RxDoctor Payments Data

Nather Ansari, MD

Internal Medicine · Stafford, VANPI 1689663320

Payments from drug & device makers

$14,086in general payments, 2019–2025

Across 807 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Amgen$946
  • Astellas Pharma US Inc$847
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,56496%
  • Education$5224%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)124$1,919
Pfizer76$1,145
Lilly USA, LLC56$1,043
AstraZeneca(2 entities)56$1,013
Amgen(2 entities)50$946
Astellas Pharma US Inc31$847
GSK55$772
Novo Nordisk38$770
Johnson & Johnson32$547
Melinta Therapeutics, LLC30$525
Novartis29$487
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$309
Bayer16$304
Sunovion Pharmaceuticals Inc.13$237
Merck18$216
Abbott11$212
Xeris Pharmaceuticals, Inc.6$194
Biohaven Pharmaceutical Holding Company Ltd.20$189
Otsuka America Pharmaceutical, Inc.8$169
E.r. Squibb & Sons, L.L.C.10$163
Amarin Pharma, Inc.8$152
Sanofi-aventis U.S. LLC7$140
Sumitomo Pharma America, Inc.5$121
Lundbeck LLC6$118
UCB, Inc.5$109
Exact Sciences3$81
Dexcom, Inc.4$81
Genentech USA, Inc.5$78
Scilex Pharmaceuticals Inc.4$74
Supernus Pharmaceuticals, Inc.4$71
Verona Pharma, Inc.4$70
Kowa Pharmaceuticals America, Inc.4$65
Ardelyx, Inc.3$64
Teva Pharmaceuticals USA, Inc.4$59
Boehringer Ingelheim3$58
Nabriva Therapeutics, PLC3$53
Mylan Specialty L.p.2$48
Hikma Pharmaceuticals USA3$47
Biohaven Pharmaceuticals, Inc.2$43
Antares Pharma, Inc.2$39
Esperion Therapeutics, Inc.2$36
Avanir Pharmaceuticals, Inc.2$33
Paratek Pharmaceuticals, Inc.2$33
Eyevance Pharmaceuticals LLC2$33
Biogen2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$29
Ironwood Pharmaceuticals, Inc2$29
Cequr Corporation1$28
Amneal Pharmaceuticals LLC1$28
Takeda Pharmaceuticals U.S.A., Inc.2$27
Boston Scientific1$23
Insulet Corporation1$22
Cumberland Pharmaceuticals, Inc.1$22
Eisai Inc.1$18
Axsome Therapeutics, Inc.1$17
Corcept Therapeutics1$16
CMP Pharma, Inc.1$15
Baxter Healthcare1$15
Halozyme Inc1$14
Medtronic1$13

How this compares

$14,086 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$267,504
Medicare patients
968
Services billed
7,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$80,101
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$70,341
TrulicityDulaglutide55$60,920
MounjaroTirzepatide34$46,610
OzempicSemaglutide40$41,998
TradjentaLinagliptin50$40,805
LinzessLinaclotide49$38,150
JanumetSitagliptin Phos/Metformin Hcl29$34,798
JanuviaSitagliptin Phosphate24$31,145
RybelsusSemaglutide28$30,835
XareltoRivaroxaban27$23,941
InvokanaCanagliflozin13$21,614
FarxigaDapagliflozin Propanediol19$20,722
Janumet XrSitagliptin Phos/Metformin Hcl28$20,489
MyrbetriqMirabegron23$17,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,043$107,53089 claims
MerckJanumet, Januvia, Janumet Xr$216$86,43281 claims
GSKTrelegy Ellipta, Breo Ellipta$772$82,946115 claims
PfizerEliquis$1,145$80,101103 claims
Novo NordiskOzempic, Rybelsus$770$72,83368 claims
Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat$58$66,22080 claims
Johnson & JohnsonXarelto, Invokana$547$45,55540 claims
AbbVieLinzess$1,919$38,15049 claims
AstraZenecaFarxiga, Symbicort$1,013$26,82845 claims
Astellas Pharma US IncMyrbetriq$847$17,58323 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$3,485333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Stafford

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →